Alfred K. Cheung

Alfred K. Cheung

Auto-generated profile, based on publicly available information

Alfred K. Cheung

Division of Nephrology and Hypertension, University of Utah, Salt Lake City, Utah

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2000 in Kidney International
Verified
Journal Article
Closed access
ACAlfred K. Cheung
Alfred K. Cheung
MSMark J. Sarnak
Mark J. Sarnak
GYGuofen Yan
Guofen Yan
JDJohanna Dwyer
Johanna Dwyer
RHRobert J. Heyka
Robert J. Heyka
ALAndrew S. Levey
Andrew S. Levey

22 June 2017 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
ACAlfred K. Cheung
Alfred K. Cheung
MRMahboob Rahman
Mahboob Rahman
DRDavid M. Reboussin
David M. Reboussin
TCTimothy E. Craven
Timothy E. Craven
TGTom Greene
Tom Greene
FGfor the SPRINT Research Group
for the SPRINT Research Group
The appropriate target for BP in patients with CKD and hypertension remains uncertain. We report prespecified subgroup analyses of outcomes in participants with baseline CKD in the Systolic Blood Pressure Intervention Trial. We randomly assigned participants to a systolic BP target of <120 mm Hg (intensive group; n=1330) or <140 mm Hg (standard group; n=1316). After a median follow-up of 3.3 years, the primary composite cardiovascular outcome occurred in 112 intensive group and 131 standard group CKD participants (hazard ratio [HR], 0.81; 95% confidence interval [95% CI], 0.63 to 1.05). The intensive group also had a lower rate of all-cause death (HR, 0.72; 95% CI, 0.53 to 0.99). Treatment effects did not differ between participants with and without CKD (P values for interactions ≥0.30). The prespecified main kidney outcome, defined as the composite of ≥50% decrease in eGFR from baseline or ESRD, occurred in 15 intensive group and 16 standard group participants (HR, 0.90; 95% CI, 0.44 to 1.83). After the initial 6 months, the intensive group had a slightly higher rate of change in eGFR (−0.47 versus −0.32 ml/min per 1.73 m2 per year; P<0.03). The overall rate of serious adverse events did not differ between treatment groups, although some specific adverse events occurred more often in the intensive group. Thus, among patients with CKD and hypertension without diabetes, targeting an SBP<120 mm Hg compared with <140 mm Hg reduced rates of major cardiovascular events and all-cause death without evidence of effect modifications by CKD or deleterious effect on the main kidney outcome.

1 June 2004 in Kidney International
Verified
Journal Article
Open access
PDF file
ACAlfred K. Cheung
Alfred K. Cheung
MSMark J. Sarnak
Mark J. Sarnak
GYGuofen Yan
Guofen Yan
MBMichael Berkoben
Michael Berkoben
RHRobert Heyka
Robert Heyka
FGfor the Hemo Study Group
for the Hemo Study Group
Cardiac disease is the leading cause of death among prevalent maintenance dialysis patients, accounting for approximately 45% of reported deaths in the United States [ 1. x 1. U.S. Renal Data System. Cardiovascular special studies. in: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2002 Google Scholar See all References , 2. x 2. U.S. Renal Data System. Mortality & causes of death. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2002 Google Scholar See all References ]. Compared with the general population, dialysis patients have a 10 to 20 times greater incidence of cardiovascular death [ 3 x 3. Foley, R.N., Parfrey, P.S., and Sarnak, M.J. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998; 9: S16–23 Crossref | PubMed | Scopus (26) | Google Scholar See all References ] [3] . This excess cardiac mortality is, in part, caused by a high prevalence of cardiac disease before initiation of dialysis [ 4. x 4. Stack, A.G. and Bloembergen, W.E. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol. 2001; 12: 1516–1523 PubMed | Google Scholar See all References , 5. x 5. Foley, R.N. and Parfrey, P.S. Cardiac disease in chronic uremia: Clinical outcome and risk factors. Adv Ren Replace Ther. 1997; 4: 234–248 PubMed | Google Scholar See all References ], and is likely caused by the high prevalence of cardiovascular risk factors in patients with progressive kidney disease [ 4. x 4. Stack, A.G. and Bloembergen, W.E. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol. 2001; 12: 1516–1523 PubMed | Google Scholar See all References , 5. x 5. Foley, R.N. and Parfrey, P.S. Cardiac disease in chronic uremia: Clinical outcome and risk factors. Adv Ren Replace Ther. 1997; 4: 234–248 PubMed | Google Scholar See all References , 6. x 6. Fung, F., Sherrard, D.J., Gillen, D.L. et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis. 2002; 40: 307–314 Abstract | Full Text | Full Text PDF | PubMed | Scopus (97) | Google Scholar See all References ]. In addition, dialysis patients with cardiac disease have a higher case-fatality rate than nondialysis patients with heart disease [ 7 x 7. Herzog, C.A., Ma, J.Z., and Collins, A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl Med. 1998; 339: 841–843 Crossref | PubMed | Scopus (710) | Google Scholar See all References ] [7] . These data indicate an urgent need to identify the types of cardiac diseases, the risk factors for cardiac disease, and the strategies for prevention and treatment of cardiac diseases in patients with chronic kidney disease.

1 February 2006 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
ACAlfred K. Cheung
Alfred K. Cheung
MRMichael V. Rocco
Michael V. Rocco
GYGuofen Yan
Guofen Yan
JLJohn K. Leypoldt
John K. Leypoldt
NLNathan W. Levin
Nathan W. Levin
GEGarabed Eknoyan
Garabed Eknoyan
In the randomized Hemodialysis (HEMO) Study, chronic high-flux dialysis, as defined by higher β-2 microglobulin (β2M) clearance, compared with low-flux dialysis did not significantly alter all-cause mortality in the entire cohort but was associated with lower mortality in long-term dialysis patients. This analysis examined the determinants of serum β2M levels and the associations of serum β2M levels or dialyzer β2M clearance with mortality. In a multivariable regression model that examined 1704 patients, baseline residual kidney urea clearance and dialyzer β2M clearance were strong predictors of predialysis serum β2M levels at 1 mo of follow-up, with regression coefficients of −7.21 (±0.69 SE) mg/L per ml/min per 35 L urea volume (P < 0.0001) and −1.94 (±0.30) mg/L per ml/min (P < 0.0001),respectively. In addition, black race and baseline years on dialysis correlated positively whereas age, diabetes, serum albumin, and body mass index correlated negatively with serum β2M levels (P < 0.05). In time-dependent Cox regression models, mean cumulative predialysis serum β2M levels but not dialyzer β2M clearance were associated with all-cause mortality (relative risk = 1.11 per 10-mg/L increase in β2M level; 95% confidence interval 1.05 to 1.19; P = 0.001), after adjustment for residual kidney urea clearance and number of prestudy years on dialysis. This association is supportive of the potential value of β2M as a marker to guide chronic hemodialysis therapy.

1 March 2021 in Kidney International
Verified
Journal Article
Open access
ACAlfred K. Cheung
Alfred K. Cheung
TCTara I. Chang
Tara I. Chang
WCWilliam C. Cushman
William C. Cushman
SFSusan L. Furth
Susan L. Furth
FHFan Fan Hou
Fan Fan Hou
JMJohannes F.E. Mann
Johannes F.E. Mann
The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis represents an update to the KDIGO 2012 guideline on this topic. Development of this guideline update followed a rigorous process of evidence review and appraisal. Guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence. The strength of recommendations is based on the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. The scope includes topics covered in the original guideline, such as optimal blood pressure targets, lifestyle interventions, antihypertensive medications, and specific management in kidney transplant recipients and children. Some aspects of general and cardiovascular health, such as lipid and smoking management, are excluded. This guideline also introduces a chapter dedicated to proper blood pressure measurement since all large randomized trials targeting blood pressure with pivotal outcomes used standardized preparation and measurement protocols adhered to by patients and clinicians. Based on previous and new evidence, in particular the Systolic Blood Pressure Intervention Trial (SPRINT) results, we propose a systolic blood pressure target of less than 120 mm Hg using standardized office reading for most people with chronic kidney disease (CKD) not receiving dialysis, the exception being children and kidney transplant recipients. The goal of this guideline is to provide clinicians and patients a useful resource with actionable recommendations supplemented with practice points. The burden of the recommendations on patients and resources, public policy implications, and limitations of the evidence are taken into consideration. Lastly, knowledge gaps and recommendations for future research are provided.

1 April 2007 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
BKBonnie C.H. Kwan
Bonnie C.H. Kwan
FKFlorian Kronenberg
Florian Kronenberg
SBSrinivasan Beddhu
Srinivasan Beddhu
ACAlfred K. Cheung
Alfred K. Cheung
Yslipidemia is an established cardiovascular (CV) risk factor in the general population. In chronic kidney dis- ease (CKD), however, epidemiologic studies (1-3) and clinical trials (4-12) have raised uncertainties regarding the impact of dyslipidemia on clinical outcomes and, consequently, the opti- mal lipid profile. In this article, we review the pathophysiology of dyslipidemia in CKD and dialysis patients and its association with clinical outcome and the effects of therapy and compare them with those in the general population. Kidney transplant patients are excluded from the discussion. Dyslipidemia is empirically defined here as plasma lipid and lipoproteins that are associated with adverse outcomes such as CV disease (CVD) in the general population. Whether this definition is justified in patients with CKD requires further investigations. Normal Structure and Function of Lipoproteins Lipoproteins Lipoproteins consist of lipids and proteins (known as apoli- poproteins (apo)), with the main function of transporting wa- ter-insoluble lipids such as cholesterol or triglycerides in plasma from the sites of absorption (gut) and/or synthesis (liver) to the sites of utilization (peripheral tissues) or process- ing. Besides contributing to the structure and the stability of the macromolecule, apolipoproteins control the metabolism of the lipoproteins by activation or inhibition of enzymes and inter- action with lipoprotein receptors. The major types of the plasma lipoproteins and their apolipoprotein components and physiologic functions are briefly presented in Table 1.